Table 3

Summarising the available studies with oral cyproheptadine in children

CitationStudy groupStudy typeInvestigational productComparatorPrimary outcomeKey result
Visitsunthorn et al266 patients (age 4–9 years) with cold urticariaDouble-blind cross-over studyCyproheptadineKetotifenClinical symptomsNo significant difference
Wu et al2749 patients (age 2–12 years) with perennial allergic rhinitisOpen-label, randomised controlled trialLoratadineCyproheptadineTotal symptom scoreSignificantly greater reduction in symptom scores in the loratadine group
Lewis et al2830 patients (age 3–18 years) diagnosed with migraineChart reviewCyproheptadineNo comparatorHeadache frequencyOverall positive response rate for cyproheptadine was 83%
Rodriguez et al3080 patients (age 9 months–20 years) with dyspeptic symptomsChart reviewCyproheptadineNo comparatorResolved dyspeptic symptomsResponse to therapy was reported in 55% of patients
Sant'Anna et al29127 patients (age 7 months–6 years) with poor weight gainChart reviewCyproheptadineNo comparatorWeight changeA significant improvement in weight was observed compared with baseline